Preeclampsia
    3.
    发明授权

    公开(公告)号:US11717531B2

    公开(公告)日:2023-08-08

    申请号:US16847499

    申请日:2020-04-13

    申请人: ASTON UNIVERSITY

    摘要: The invention provides a method of treating preeclampsia, fetal growth restriction (FGR or IUGR), obesity in pregnancy, post-partum cardiomyopathy (heart failure in mothers), cancer and diabetic retinopathy, cardiomyopathy, myocardial infarction, wet microdegeneration and other disorders where angiogenesis is aberrant either diminished or exacerbated, comprising modulating the activity of micro RNA (miRNA). Also provided are an MiRNA modulator or a combination thereof or functional fragments or homologues thereof for use in the treatment of preeclampsia, fetal growth restriction, obesity in pregnancy, cancer, and diabetic retinopathy, cardiomyocyte infarction, wet microdegeneration as well as other disorder where angiogenesis is aberrant either diminished or exacerbated. Methods of modulating angiogenesis and pharmaceutical compositions using miR-122, miR-374b or inhibitors of miR-152 or miR195 are also provided together with methods of diagnosis using the miRNAs.

    Therapeutic material
    4.
    发明授权

    公开(公告)号:US11311646B2

    公开(公告)日:2022-04-26

    申请号:US16464561

    申请日:2017-11-29

    申请人: ASTON UNIVERSITY

    发明人: Richard Martin

    摘要: A bioactive glass composition for use in treating bone cancer includes 0.5-10 mol % gallium oxide or 1.0-20 mol % gallium nitrate/halide; 25 to 75 mol % silicon dioxide; 10 to 30 mol % calcium oxide and/or strontium oxide; up to 30 mol % sodium oxide; and up to 15 mol % phosphorous pentoxide. It may further comprise magnesium and/or potassium oxide. The bioactive glass composition may be positioned within a patient's bone post-surgery to promote apatite formation and to release gallium ions having a toxic effect on any remaining cancerous cells.

    Diagnostic Assay and Treatment for Preeclampsia

    公开(公告)号:US20200038354A1

    公开(公告)日:2020-02-06

    申请号:US16516597

    申请日:2019-07-19

    申请人: Aston University

    IPC分类号: A61K31/198 G01N33/68

    摘要: The invention provides a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.

    Hydrogen sulphide compounds
    6.
    发明授权

    公开(公告)号:US10195220B2

    公开(公告)日:2019-02-05

    申请号:US14771285

    申请日:2014-03-03

    申请人: Aston University

    IPC分类号: A61K31/675 A61K31/095

    摘要: The application describes Hydrogen Sulphide (H2S), or a (H2S) generating compound or compound capable of stimulating H2S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.

    Mode division multiplexed passive optical network

    公开(公告)号:US10193619B2

    公开(公告)日:2019-01-29

    申请号:US15762386

    申请日:2016-09-22

    申请人: ASTON UNIVERSITY

    摘要: A method of compensating for crosstalk in a mode division multiplexing passive optical network using a technique of transmitter-side crosstalk pre-compensation, performed at the Central Office, in which a downlink reference signal such as a training sequence or pilot signal is retrieved at the transmitter without being influenced by crosstalk effects on its uplink transmission. An uplink reference signal is transmitted in a quasi-single mode transmission along the optical fiber, and a plurality of optical signals input to transmission multiplexer are adapted based on the uplink reference signal to pre-compensate for crosstalk.